AMGN Amgen Inc

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

NewAmsterdam Pharma Company N.V.

(Name of Issuer)

Ordinary Shares, nominal value EUR 0.12 per share

(Title of Class of Securities)

N62509109

(CUSIP Number)

August 22, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

ITEM 1.

(A) NAME OF ISSUER:

NewAmsterdam Pharma Company N.V. (the “Issuer”)

(B) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICE:

Gooimeer 2-35, 1411 DC Naarden, The Netherlands

ITEM 2.

(A) NAME OF PERSON FILING:

This statement is filed on behalf of:

Saga Investments Coöperatief U.A.

Amgen Singapore Manufacturing Pte. Ltd.

Amgen Technology, Limited

Onyx Pharmaceuticals, Inc.

Amgen Inc.

(B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

The address for Saga Investments Coöperatief U.A. is Minervum 7061, 4817 ZK Breda, The Netherlands.

The address for Amgen Singapore Manufacturing Pte. Ltd. is 1 Tuas View Drive, Singapore 637026.

The address for Amgen Technology, Limited is Victoria Place, 5th Floor 31 Victoria Street Hamilton HM 10, Bermuda.

The address for Onyx Pharmaceuticals, Inc. and Amgen Inc. is One Amgen Center Drive, Thousand Oaks, California 91320-1799.

(C) CITIZENSHIP:

Saga Investments Coöperatief U.A. is a cooperative formed in the Netherlands.

Amgen Singapore Manufacturing Pte. Ltd. is a private limited company formed in Singapore.

Amgen Technology, Limited is a company formed in Bermuda.

Onyx Pharmaceuticals, Inc. is a Delaware corporation.

Amgen Inc. is a Delaware corporation.

Each of Saga Investments Coöperatief U.A., Amgen Singapore Manufacturing Pte. Ltd., and Amgen Technology, Limited are indirect subsidiaries of Amgen Inc., and Onyx Pharmaceuticals, Inc. is a wholly owned subsidiary of Amgen Inc.

(D) TITLE OF CLASS OF SECURITIES:

Ordinary Shares, nominal value EUR 0.12 per share (the “NewAmsterdam Ordinary Shares”)

(E) CUSIP NUMBER:

N62509109

ITEM 3. STATEMENT FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B) OR (C)

Not applicable.

ITEM 4. OWNERSHIP.

(a), (b) and (c)—The information contained on the cover pages to this Schedule 13G are incorporated herein by reference.

Upon our initial Schedule 13G filing on December 2, 2022, Saga Investments Coöperatief U.A. was the record holder of 4,910,000 NewAmsterdam Ordinary Shares, Amgen Singapore Manufacturing Pte. Ltd. was the sole shareholder of Saga Investments Coöperatief U.A.; Amgen Technology, Limited was the sole shareholder of Amgen Singapore Manufacturing Pte. Ltd.; and Onyx Pharmaceuticals, Inc. and Amgen Inc. were the shareholders of Amgen Technology, Limited (the “Amgen Inc. Group”).

Between July 8, 2024 and August 22, 2024, all of the NewAmsterdam Ordinary Shares held by the Amgen Inc. Group were sold.

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

Not applicable.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON

Not applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

Not applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP

Not applicable.

ITEM 10. CERTIFICATION.

Not applicable.

Signatures

After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: August 23, 2024

Exhibit Index

Exhibit 99.1

Joint Filing Agreement

The undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Dated: August 23, 2024